Abstract
Natural killer (NK) cells are large granular lymphocytes of the innate immune system first described four decades ago for their ability to recognize and kill target cells a priori<Emphasis Type=–Italic—></Emphasis>without prior experience of the target—and in a manner that is antigen unrestricted. Because of recent advances in understanding the mechanisms of NK-cell target recognition and the diversity within the NK-cell repertoire, we now recognize that NK cells play an important role in cancer immunosurveillance. Acute myeloid leukemias are among the most well characterized of NK-cell-sensitive malignancies, and differences in NK-cell genotype, phenotype, and function correlate with disease progression and predict therapeutic responses. The ability to generate clinical-grade therapeutic products of sufficient purity, number, and function has only recently allowed NK-cell immunotherapy to be pursued in clinical trials as monotherapy, in combination with monoclonal antibodies or immunomodulating drugs, and within the setting of hematopoietic stem cell transplantation.
Original language | English (US) |
---|---|
Title of host publication | Targeted Therapy of Acute Myeloid Leukemi |
Publisher | Springer New York |
Pages | 737-755 |
Number of pages | 19 |
ISBN (Electronic) | 9781493913930 |
ISBN (Print) | 9781493913923 |
DOIs | |
State | Published - Jan 1 2015 |
Keywords
- Adoptive immunotherapy
- Cellular therapy
- Haploidentical stem cell transplantation
- InnateiImmunity
- Nk cells
ASJC Scopus subject areas
- General Medicine
- Pharmacology, Toxicology and Pharmaceutics(all)
- General Biochemistry, Genetics and Molecular Biology
- General Immunology and Microbiology